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Abstract
Reactive oxygen species, ROS, are regulators of endothelial cell migration, proliferation and survival, events critically
involved in angiogenesis. Different isoforms of ROS-generating NOX enzymes are expressed in the vasculature and provide
distinct signaling cues through differential localization and activation. We show that mice deficient in NOX1, but not NOX2
or NOX4, have impaired angiogenesis. NOX1 expression and activity is increased in primary mouse and human endothelial
cells upon angiogenic stimulation. NOX1 silencing decreases endothelial cell migration and tube-like structure formation,
through the inhibition of PPARa, a regulator of NF-kB. Administration of a novel NOX-specific inhibitor reduced
angiogenesis and tumor growth in vivo in a PPARa dependent manner. In conclusion, vascular NOX1 is a critical mediator of
angiogenesis and an attractive target for anti-angiogenic therapies.
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Introduction
Angiogenesis is a complex process occurring in physiological
situations such as embryogenesis and wound repair, and
contributes to pathological conditions such as diabetes, psoriasis,
arthritis and cancer. Angiogenesis is a critical determinant of
cancer progression. In its absence, tumors are unable to grow
beyond the size of microscopic lesions and persist as dormant, non-
expanding nodules [1,2]. Tumor cells, stromal cells and infiltrating
bone marrow-derived cells can initiate angiogenesis through a
process called angiogenic switch in which secretion of pro-
angiogenic factors is increased and/or production of endogenous
anti-angiogenic factors is reduced [3,4]. Angiogenic vessels are
mostly formed by sprouting of endothelial cells from the existing
vasculature. This process involves degradation of the surrounding
matrix, cell proliferation, migration, differentiation, and tube
formation [5]. Inhibition of angiogenesis has recently been
introduced in the clinics as novel therapeutic option to block
cancer progression [6].
NADPH oxidases are enzymes that produce reactive oxygen
species (ROS). Depending on concentration and sub-cellular
localization, ROS can mediate a variety of cellular functions,
including pathogen killing, cell migration, proliferation and
differentiation (for review [7]). The NADPH oxidase (NOX)
family of proteins consists of seven isoforms (NOX1-5 and DUOX
1-2), which transport electrons across membranes, thereby
reducing oxygen into superoxide. Depending on the isoform,
these catalytic transmembrane proteins form a complex with
p22phox and the cytoplasmic subunits p67phox/NOXO1, p47phox/
NOXA1, p40phox and Rac1/2 [7]. The NOX1 isoform is
expressed in epithelial cells, retinal pericytes, osteoclasts, vascular
smooth muscle and endothelial cells [8–16]. While increased
NOX1 expression has been reported in cases of colon cancer [17],
it has been suggested that this may correlate with inflammation
rather than tumorigenesis [18,19]. However, experimental
overexpression of NOX1 in fibroblasts or carcinoma cells induced
an angiogenic switch mediated by the increased production of
VEGF and MMPs [20]. Moreover NOX1 has been shown to
regulate apoptosis and morphogenesis of sinusoid endothelial cells
in vitro [16].
The nuclear hormone receptors peroxisome proliferator-
activated receptors (PPAR) dimerize with the retinoid X receptor.
Upon activation by lipids, this complex regulates gene transcrip-
tion by binding to peroxisome proliferator-responsive elements.
PPARa, a member of the family, was shown to mediate anti-
inflammatory activity through inhibition of the transcription factor
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NF-kB. In the vascular system, PPARa inhibits NF-kB transacti-
vation either by direct interaction with the p65 subunit or by up-
regulation of I-kB, the NF-kB inhibitory subunit [21,22]. In
different tumor models, activation of PPARa by agonists blocks
tumor growth and angiogenesis by reducing production of
proangiogenic factors such as VEGF or epoxyeicosatrienoic acids
[23–25]. In human endothelial cells, PPARa activators also inhibit
cytokine-induced expression of adhesion molecules and chemo-
kines [26].
In this study, we analyzed the role of NOX1 in human and
mouse angiogenesis and observed an increased expression and
activity of NOX1 during the angiogenic switch. Furthermore,
blood vessel formation in NOX1-deficient mice was dramatically
reduced in response to angiogenic factors and in tumors. NOX1
deficiency also lead to reduced endothelial cell migration and
reduced formation of tube-like structures. We analyzed the
mechanism by which NOX1 regulates angiogenesis and showed
that NOX1 down-regulates expression and activity of the anti-
inflammatory and anti-angiogenic nuclear receptor PPARa.
Results
NOX1-deficient mice show impaired angiogenesis
In order to test whether NOX-dependent ROS production
participates in blood vessel formation, we performed in vivo
Matrigel angiogenesis assays using mice deficient for different
NOX isoforms. Matrigel was preloaded with the angiogenic factor
bFGF and implanted subcutaneously into wild type (WT) or
NOX-deficient mice. Subcutaneous Matrigel plug vascularization
quantified by X-Ray-based computer tomography in animals
deficient for NOX2 or NOX4 had angiogenic responses
indistinguishable from WT mice. By contrast, Matrigel plug
vascularization was reduced by 47% 67.6 and 65% 613.2 in
NOX1 knockout and NOX1/2 double knockout animals
respectively, as compared to WT mice (Figure 1a). This difference
is noticeable on macroscopic images of Matrigel plugs following
excision (Figure 1b). Immunostaining of plugs with the vascular
marker PECAM-1 demonstrated reduced PECAM-1-positive areas
in NOX1-and NOX1/2-deficient mice (56% 62 and 46% 6
3 respectively) compared toWT animals (Figure 1c,d). Remarkably,
plugs in NOX1-and NOX1/2-deficient mice were lacking large
vessels while the number of small vessels significantly increased
(Figure 1e).
From these results, we conclude that NOX1 is essential for
bFGF-induced angiogenesis.
NOX1 expression and activity are up-regulated by
proangiogenic factors
To determine whether the aberrant angiogenesis observed in
NOX1-deficient mice was due to impaired endothelial cell
function; we studied the effect of NOX1 inhibition on mouse
lung endothelial cells (MLEC) [27] (Figure S1), murine thymic
endothelioma (tEnd) cells and primary human umbilical vein-
derived endothelial cells (HUVEC). We first studied the expression
level of NOX1 in these cells under basal conditions and in
response to stimulation with the angiogenic factors VEGF or
bFGF at 20 ng/ml for 3 hours. Quantitative real-time PCR
revealed 2–3 fold up-regulation of NOX1 mRNA expression in all
endothelial cells after angiogenic stimulation (Figure 2a–c).
Expression of NOX4 and NOX2 did not change upon VEGF
or bFGF stimulation (data not shown). While endothelial NOX4
expression level was high, NOX2 was found to be very low.
Next, we analyzed ROS production in murine and human
endothelial cells in response to VEGF and bFGF stimulation. As
expected, these factors increased intracellular ROS levels
(Figure 2g–i), while in NOX1-deficient MLEC, ROS production
in response to VEGF or bFGF stimulation was absent or severely
compromised (Figure 2d,g). This is in contrast to NOX4
deficiency, which did not affect ROS production, induced by
VEGF or bFGF. These data were consistent with observed
deficient ROS production by endothelial cells following NOX1
silencing (Figure 2i and data not shown). Additionally, cells treated
with the pharmacological NOX inhibitor GKT136901 did not
induce ROS after VEGF or bFGF stimulation (Figure 2d–i). The
specific NADPH oxidase inhibitor GKT136901 was identified by
screening more than 130,000 molecules [28]. In a NOX subunit
specific cell-free system [29,30], GKT136901 inhibits NOX1 with
high affinity (Ki = 160610 nM), similar to the irreversible
flavoprotein inhibitor Diphenyliodonium (DPI; Ki = 70610 nM)
(Figure 3a). However, DPI shows the same potency on NOX4
(Ki = 70 nM), NOX2 (Ki = 70 nM) and xanthine oxidase
(Ki = 50 nM). In contrast, GKT136901 is more specific for
NOX1 and NOX4 with a ten-fold lower potency on NOX2 (Ki =
1530690 nM) and almost no affinity for xanthine oxidase
(Ki.100 mM) (Figure 3b and Figure S2). Moreover,
GKT136901 completely inhibits oxidase activity of NOX1 and
NOX4 but has only a partial effect on NOX2 (Figure S2). In order
to demonstrate the specificity of GKT136901 for NOX enzymes,
a pharmacological profiling of 135 different targets was performed
including ROS producing and redox-sensitive enzymes [31].
GKT136901 at 10 mM showed low or no inhibition demonstrat-
ing the high degree of specificity of this compound (Table S1).
Taken together, the results obtained with NOX1 deficient cells
and the inhibitor GKT136901 demonstrate that NOX1 is
responsible for ROS production in endothelial cells stimulated
with the pro-angiogenic factors VEGF or bFGF.
NOX1 mediates endothelial cell migration and sprouting
Angiogenesis requires endothelial cell proliferation, sprouting
and migration [5]. To identify the NOX1-dependent step in
angiogenesis, we performed different in vitro functional assays. Cell
proliferation was not altered in NOX1-deficient MLEC, nor in
NOX1 silenced cells (data not shown). However, cell migration
and tube formation of MLEC from NOX1-deficient animals was
significantly reduced as compared to WT cells (Figure 4a, d). We
also observed an inhibition of endothelial cell migration and tube
formation in MLEC treated with the NOX1 inhibitor
GKT136901 (Figure 4) and NOX-dependent ROS blocking
agents (Figure S3) [32,33]. Furthermore, silencing of NOX1
expression using siRNA in mouse and human endothelial cells
significantly reduced migration (17% 65.7 and 24% 63.8 of
migrating area reduction respectively) and formation of tube-like
structures (28% 64.8 and 34% 614 of reduction in skeleton
length respectively) (Figure 4c, e and f). We did not observe any
inhibition of migration or tube formation with MLEC derived
from NOX4-deficient mice or with cells in which NOX4 was
silenced using siRNA (Figure 4a, c, d and f).
Moreover, using a NOX1 expressing vector we observed that
NOX1 overexpression (thirteen-fold increase) is sufficient to
increase endothelioma cell migration and tube-like structure
formation (Figure S4).
These experiments demonstrate that NOX1 is an important
protein involved in migration and tube-like structure formation of
endothelial cells with no detectable role in cell proliferation.
NOX1 down-regulates PPARa expression
PPARa is a nuclear hormone receptor with anti-inflammatory
functions able to block the angiogenic activity of VEGF
NOX1 a New Angiogenic Factor
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[23,34,35]. We observed that NOX1-deficient MLEC expressed
5-fold higher PPARa compared to WT MLEC (Figure 5a), while
no difference was seen with PPARc expression (data not shown).
This up-regulation of PPARa expression was also observed in
endothelial cell lines silenced for NOX1 (Figure 5a), and was
dependent on PPARa transactivation. Indeed, when NOX1-
silenced cells were incubated with the PPARa antagonist
GW6471, PPARa up regulation was no longer observed (data
not shown). This suggests that the deficiency in migration and tube
formation observed in NOX1-deficient endothelial cells may
depend on up-regulation of PPARa expression and transcriptional
activity.
To test this hypothesis, we treated NOX1-deficient MLEC with
the PPARa antagonist GW6471 and found that the compound
restored cell migration and tube formation compared to untreated
NOX1-deficient cells (Figure 5b–c). Moreover, PPARa-deficient
endothelial cells isolated from PPARa-deficient mice migrated
more than WT endothelial cells. As expected, inhibition of NOX1
using the inhibitor GKT136901 in PPARa-deficient cells did not
affect endothelial cell migration or invasion (data not shown).
Taken together, these results indicate that NOX1 promotes
endothelial cell migration and sprouting by suppressing PPARa
expression and activity.
NOX1 promotes NF-kB activation in response to
angiogenic stimulation by PPARa inhibition
We then set out to further identify the vascular NOX1 signaling
pathways implicated in angiogenesis. Activation of both Akt and
ERK1/2 were observed following 10 minutes of stimulation with
the angiogenic factor bFGF. In NOX1-deficient MLEC, Akt
activation was reduced compared to WT cells, while ERK1/2
activation was unaffected (Figure S5). These results showed that
NOX1 is involved in the activation of the Akt signaling pathway in
response to bFGF. Since NOX1 suppresses PPARa expression,
Figure 1. NOX1 deficient mice exhibit reduced angiogenic capacity. Matrigel was loaded with 500 ng/ml bFGF and implanted
subcutaneously into NOX deficient mice. After one week, iodinated liposomes were injected i.v. and the plugs analyzed by X-ray tomography. (a)
Quantification of matrigel plug vascularization. Graph shows mean of grey density 6 s.e.m. For WT, NOX1 KO and NOX1/2 KO n= 8 and for NOX2 KO
and NOX4 KO n=6. (b) Photographs of excised plugs, scale bars represent 1 cm. c. Blood vessel density in plugs from the experiment in (a). Graph
shows percentage of PECAM-1 positive area 6 s.e.m. (d). Photographs of PECAM-1 immunostaining, PECAM-1 in green, nuclei in blue, scale bars
represent 20 mm. Images were acquired with a 20x/0.5 numeric aperture lens and analyzed using LSM510 Meta confocal microscope (Carl Zeiss).
e. Vessel size analysis; vessel with lumen under 20 mm are considered as small (black), from 20 to 50 medium (dark grey) and over 50 mm as large
(light grey) 6 s.e.m. Anova p,0.01; * p,0.05, ** p,0.01, *** p,0.001.
doi:10.1371/journal.pone.0014665.g001
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this is also consistent with the literature describing PPARa as
inhibitor of VEGF signaling through blocking of Akt but not
ERK1/2 activation.
Since PPARa is known to inhibit NF-kB activation, we
monitored NF-kB activation in NOX1-deficient MLEC in
response to VEGF or bFGF stimulation (30 minutes). NOX1-
deficient MLEC showed reduced nuclear translocation of the NF-
kB p65 subunit compared to WT cells in response to VEGF or
bFGF as demonstrated by Western blotting on nuclear extracts
and immunofluorescence of endothelial cells (Figure 5d and Figure
S6). Using endothelial cell lines, we then demonstrated that
inhibition of NF-kB translocation depended on PPARa activation.
Indeed, in NOX1-silenced cells PPARa expression was up-
regulated (Figure 5a). When these cells were treated with the
PPARa antagonist GW6471 before angiogenic stimulation,
deficient nuclear translocation of NF-kB was no longer observed
(Figure 5e and Figure S6). Moreover in NOX1 deficient cells,
PPARa and NF-kB target genes were deregulated (Table 1). For
example: Vascular NOX1 deficiency leads to upregulation of the
anti-oxidant genes catalase, gluthatione peroxydase-3 and the anti-
migratory gene VE-Cadherin, while downregulating the proan-
giogenic genes MMP2, MMP9, uPAR, VEGF and bFGF.
Incubation of NOX1 silenced cells with the PPARa antagonist
GW6471 blocked this effect, suggesting that regulation of these
was dependent on PPARa activity (Table 1).
Host NOX1 promotes tumor angiogenesis and tumor
progression
The above findings led us to investigate whether NOX1 may
contribute to tumor progression by promoting tumor vasculariza-
tion. To this end, we implanted tumorigenic B16F0 melanoma
cells or Lewis Lung Carcinoma (LLC1) cells subcutaneously into
WT and NOX1-deficient mice. LLC1 cells expressed high level of
NOX1 in contrast to B16F0 cells. We observed reduced tumor
vascularization in NOX1-deficient animals with B16F0 melanoma
but not with LLC1 tumors (Figure 6a–b).
To assess whether NOX1 may be a valuable target for cancer
therapy, we used the inhibitor GKT136901. This inhibitor did not
interfere with tumor cell proliferation and apoptosis in vitro but it
impinged in their ROS producing activity (Figure S7). One day
after LLC1 injection, tumor bearing mice were treated daily by
oral administration of GKT136901 at 40 mg/kg. After one week
of treatment, the size of tumor in GKT136901-treated mice was
34% 65.8 smaller compared to tumors in vehicle-treated mice
Figure 2. NOX1 expression and activity is up-regulated by angiogenic stimuli. NOX1 expression was measured by quantitative real-time
PCR in mouse primary lung endothelial cells (MLEC, a), HUVEC (b), mouse endothelioma cell line (c) after stimulation with VEGF or b-FGF at 20 ng/ml
for 3 hours. The quantity of NOX1 mRNA was normalized to the quantity of a housekeeping gene, tubulin for mouse cells and b2-microglobulin for
human cells, 6 s.e.m, n= 3. Activity of NOX1 was evaluated by ROS measurement using DHE substrate on MLEC (d,g), HUVEC (e, h) and mouse
endothelioma (f, i). ROS production is up-regulated by VEGF and b-FGF stimulation in a NOX1-dependent manner. g, h, i. Graphs show quantification
of ROS level in endothelial cells stimulated in presence or absence of VEGF or b-FGF. g. MLEC WT (black bar), MLEC WT + GKT136901 (grey bar), MLEC
NOX1KO (white bar). h. HUVEC untreated (black bar) or treated with GKT136901 at 10 mM (grey bar). i. Mouse endothelioma cell line untreated (black
bar), treated with GKT136901 at 10 mM (grey bar), treated with NOX1 siRNA (white bar). Results are expressed in fold increase6 s.e.m, n = 3. *p,0.05,
***,0.001 using Student’s t-test.
doi:10.1371/journal.pone.0014665.g002
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(Figure 6c). This treatment had no toxic effect on mice as
illustrated by the Figure S8. Quantification of tumor vasculature
by PECAM-1 immunostaining showed 59% 69.3 reduction of
vascular area in GKT136901-treated tumors as compared to
vehicle treated animals (Figure 6d). In addition, we performed a
therapeutic assay by treating animals bearing established tumors
(i.e. starting 8 days after tumor implantation) with GKT136901 or
the anti-VEGFR2 antibody DC101, as a positive control. Tumor
volume was measured daily during treatment. Both treatments
delayed tumor progression (35%65.7 and 35%69.7 respectively)
and vascularization (36% 616 and 43% 620 respectively)
(Figure 6e, f). From these results, we conclude that NOX1 plays
a critical role in promoting tumor angiogenesis and tumor
progression.
To further analyze the link between NOX1 and PPARa in vivo,
we injected LLC1 or B16F0 tumor cells in either WT or PPARa-
deficient mice and treated these animals with the NOX1 inhibitor
GKT136901. Vascularization of these tumors was analyzed by
PECAM-1 immunostaining. In WT mice, the inhibitor blocked
LLC1 and B16F0 tumor vascularization (100% 624 vs 65% 613
and 100% 615 vs 64% 614), whereas it had no effect in PPARa
deficient mice (100%617 vs 129%623 and 100%626 vs 98%6
24) (Figure 6g,h).
From these observations, we conclude that NOX1 promotes
tumor angiogenesis by inhibiting the anti-angiogenic factor
PPARa.
Discussion
Reactive oxygen species are important players in cancer biology
[36–38]. At high levels, they induce apoptosis and/or senescence
while at homeostatic levels they influence survival and prolifera-
tion. In tumor endothelial cells, NOX enzymes contribute to
angiogenesis through ROS-dependent mechanisms, and thereby
promote tumor growth. In this study, we show that vascular
NOX1, but not NOX2 or NOX4, is an important regulator of
angiogenesis, through the modulation of endothelial migration and
tube formation. We furthermore identified that NOX1 activity
suppresses the anti-inflammatory nuclear hormone receptor
PPARa as a critical mechanism mediating these effects (Figure 7).
Inhibition of NOX1 decreases endothelial cell migration. A link
between NOX1, ROS and cell migration has been previously
described with non-endothelial cells such as colon carcinoma cell
lines [39]. In addition, Schro¨der et al. reported that blocking
NOX1 reduced FGF-stimulated migration of smooth muscle cells
through NOX1 dependent ROS activation of JNK, which in turn
phosphorylated paxillin [40]. Modulating smooth muscle cell
migration may not only be restricted to NOX1, as NOX4 showed
similar effects [41]. However, these conflicting data may be due to
the different mode of smooth muscle cell activation by bFGF and
PDGF, respectively. Based on these data, it is clear that NOX1
and derived ROS products impede the migration of vascular
smooth muscle and tumor cells. The role of NOX1 in endothelial
cell migration and angiogenesis was previously neglected probably
due to the fact that in resting endothelial cells NOX1 is expressed
at low levels and is up-regulated only during the angiogenic switch
as we show in this study.
Importantly, we do not find evidence for the involvement of the
other tested NOX isoforms 2 and 4 in bFGF-induced angiogenesis
in vivo. This is in contrast to other reports suggesting an
angiogenic role for these NOX isoforms. Angiopoietin-1, VEGF,
or thrombin-induced neovascularization in vitro and in vivo have
been suggested to be dependent on NOX2 [42–45]. Furthermore,
a recent study showed that inhibitors specific for NOX4 and
NOX2 blocked hemangioma (i.e. endothelial cell-derived tumor)
growth in vivo [33]. Other laboratories found NOX4 responsible
for basal endothelial ROS production and cell proliferation [46].
The function of NOX2 and NOX4 in angiogenesis may depend
on the type of stimulation and operate by a different mechanism
than NOX1, as both enzymes are involved in endothelial cell
Figure 3. Inhibition of NOX1-dependent ROS production by GKT136901. (a) Concentration-response curve of GKT136901 (e) and DPI (x) on
membranes prepared from NOX1 over-expressing cells. Results represent one out of four experiments performed in triplicate. Values are presented as
means 6 s.e.m. (b) Affinities of GKT136901 and DPI on NOX1, NOX2, NOX4 and Xanthine Oxidase. GKT136901 is a NADPH-oxidase specific inhibitor,
with selectivity on NOX1 and NOX4 over NOX2, whereas DPI inhibits all the NADPH oxidases tested with the same potency.
doi:10.1371/journal.pone.0014665.g003
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proliferation, while NOX1 mediates endothelial cell migration and
sprouting but not proliferation.
Our results reveal a remarkable specificity of NOX isoforms.
Clearly, endothelial cells express NOX1, NOX2, NOX4, and – at
least in humans - also NOX5. Yet, their functions appear to be
non-redundant. The specificity of NOX isoforms relies on several
elements, including different subcellular localization (NOX4 is
predominantly intracellular, while NOX1 rather localizes to
caveolae [47]), different activation mechanisms (NOX4 appears
constitutively active, while NOX1 and NOX2 are activation-
dependent, [10,48]), and there is also isoform-specific upregulation
of NOX mRNA in response to given stimuli. Most likely three
elements contribute to the unique role of NOX1 in angiogenesis: i)
its localization within caveolae is in proximity of other signaling
molecules, ii) to mediate VEGF signaling, it should be an
activation inducible enzyme, rather than constitutively active such
as NOX4; and iii) as shown in Fig. 2, its mRNA is indeed up-
regulated in response to VEGF, which adds specificity to the
system. Thus, the understanding of which NOX isoforms are
relevant for angiogenesis, provided by our study adds new
understanding of redox biology. However, the precise identifica-
tion of the NOX isoform involved in a given pathophysiological
process will also be the key for the development of specifically
targeted NOX inhibitors [49].
With respect to tumor growth, we observed differences between
NOX1-deficient mice and wildtype mice treated with the NOX
inhibitor. Indeed, while plug- and tumor-induced angiogenesis was
efficiently decreased in the NOX1-deficient mouse and by the
NOX inhibitor, the latter was markedly more efficient in
decreasing tumor growth. The most likely explanation for this
difference is the possibility that NOX enzymes within the tumor
cells are contributing to tumor growth and that the NOX inhibitor
targets these enzymes. Indeed, there is ample evidence in the
literature for a role of NOX enzymes in enhancing growth of
tumor cells [50–53]. Moreover, we found that vascularization was
substantially diminished in B16 tumors lacking endogenous
NOX1 expression, while NOX1-expressing LLC1 tumors were
normally vascularized in NOX1 deficient mice. This apparent
discrepancy is consistent with the literature, showing that
exogenous ROS impacts on endothelial cell proliferation,
migration and tube formation [54–56]. Induction of angiogenesis
may be due to NOX1 expression by LLC1 tumors, producing
high amounts of ROS in the tumor microenvironment and
modulating endothelial cell functions. This amount of ROS seems
to be sufficient to stimulate endothelial cell proliferation and
migration to form new vessels within the tumor. In the
GKT136901-treated mice, the tumor cells cannot stimulate
ROS mediated angiogenesis as the inhibitor also blocks ROS
production by LLC1 tumor cells (Figure S6c). Another obvious
difference between the NOX1-deficient mice and the NOX
inhibitor is the fact that GKT136901 efficiently inhibits NOX4, in
addition to NOX1. This point is particularly pertinent because
previous studies have implicated NOX4 in mechanisms of
angiogenesis. To understand these apparent differences, angiogenic
Figure 4. NOX1 inhibition blocks endothelial cell migration and tube-like structure formation. In vitro migration was analyzed by
wound-healing assay on mouse primary endothelial cells (a), human primary endothelial cells (b) and endothelioma cell lines (c). Tubular structure
formation was measured by 3D culture of mouse primary endothelial cells (d), human primary endothelial cells (e) or endothelioma cell lines (f).
Results are expressed in % of control 6 s.e.m, n = 3. *p,0.05, **p,0.01, ***,0.001 using Student’s t-test. GKT136901 was used at 10 mM.
doi:10.1371/journal.pone.0014665.g004
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Figure 5. NOX1 negatively regulates PPARa expression and activity. NOX1 deficiency induces an up-regulation of PPARa expression and
inhibition of pro-angiogenic signaling in endothelial cells. (a). Expression level of PPARa in MLEC and endothelioma cell lines by quantitative real-time
PCR, normalized to the tubulin expression. (b–c) PPARa antagonist, GW6471 compensated NOX1 deficiency in MLEC. (b). Migration of NOX1-deficient
MLEC in presence or absence of PPARa antagonist (10 mM). (c). Tube-like structure formation of NOX1-deficient MLEC in presence or absence of
PPARa antagonist (10 mM). VEGF and b-FGF induced-NFkB nuclear translocation is inhibited in absence of NOX1 and is dependent on PPARa activity.
(d). Western blot analysis of p65 NFkB in nuclear and cytoplasmic fractions of WT and NOX1-deficient cells stimulated 30 min with VEGF and bFGF
(20 ng/ml). (e). Western blot analysis of p65 NFkB in nuclear and cytoplasmic fractions of NOX1-silenced cells treated or not with 10 mM of GW6471
before stimulation with VEGF and bFGF. The graphs show the abundance of nuclear p65 NF-kB relative to cytoplasmic p65 NF-kB 6 s.e.m as
determined by densitometry. n = 3. * p,0.05, ** p,0.01 (Student’s t-test).
doi:10.1371/journal.pone.0014665.g005
Table 1. Expression of genes regulated by NOX1 deficiency.
LMEC NOX1 KO tEnd siRNA NOX1 tEnd siRNA NOX1 + GW 6471
Catalase 1.52±0.29 1.52±0.19 0.92±0.012
GPX3 1.47±0.08 1.49±0.13 0.70±0.01
VE-cadherin 2.29±0.07 1.54±0.28 0.9±0.2
MMP-2 0.43±0.24 0.97±0.10 2.13±0.24
MMP-9 0.29±0.13 0.89±0.13 0.47±0.07
uPAR 0.41±0.12 0.76±0.19 1.34±0.6
VEGF 0.31±0.05 2.04±0.29 0.68±0.04
bFGF 0.71±0.21 0.81±0.13 0.64±0.25
VCAM-1 0.84±0.01 0.76±0.04 0.57±0.18
Level of expression of target genes in NOX1 deficient primary endothelial cells (MLEC), or silenced cells endothelial cell lines compared to control cells, analyzed by
quantitative real-time PCR. Results are expressed in fold increase or decrease 6 s.e.m. n = 3.
doi:10.1371/journal.pone.0014665.t001
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responses should be subdivided in a proximal response of the
hypoxic tissue (HIF1a activation and VEGF production) and a
distal response of the endothelial cells (VEGF-induced neovascu-
larization). Our results (Fig. 1) clearly demonstrate that NOX4 is not
involved in the distal response of endothelial cells. However, our
results do not argue against a role of NOX4 in the proximal
response of hypoxic tissues. Indeed, based on the literature [57,58],
we think that such a role of NOX4 is likely.
Under homeostatic conditions, ROS levels are balanced by
scavenger and antioxidant enzymes. As in certain pathologies this
balance becomes deregulated and much effort has been put into
development of inhibitors of ROS production [59]. Since most
ROS-related diseases are mediated by one NOX isoform only,
novel inhibitors, which are isoform specific, will be invaluable. The
novel GenKyoTex inhibitor, GKT136901, has been developed for
this purpose and appears to be specific for NOX1 and NOX4 with
similar affinities. In vitro, this inhibitor blocked ROS production
induced by proangiogenic factors and inhibited endothelial cell
migration. More importantly, the level of this inhibition was
comparable to that observed in NOX1-deficient cells. With
NOX4-deficient endothelial cells however, we observed no
reduced migration. From these data we conclude that endothelial
cell migration is NOX1 dependent and NOX4 independent.
Furthermore, the potential for GKT136901 to be used as a
NOX1/4 specific inhibitor in prevention of tumor angiogenesis is
also demonstrated.
We observed an increase of PPARa expression when NOX1
was not expressed; suggesting that NOX1 activity constitutively
represses PPARa expression. As previously mentioned, in the
absence of NOX1 expression, endothelial cells were less able to
migrate and to form tubular structures, we showed that this effect
was reversed using an antagonist of PPARa. Moreover, in NOX1-
deficient endothelial cells, NFkB was not activated after VEGF or
bFGF stimulation. This effect was reversed by treatment with a
PPARa antagonist. In addition, anti-oxidants and anti-migratory
genes were up-regulated and pro-angiogenic genes down-regulat-
Figure 6. NOX1 inhibition reduces tumor growth and angiogenesis. B16F0 (a) or LLC1 (b) tumor cells were injected subcutaneously into WT
or NOX1 KO mice. Tumors were allowed to develop for 10 days and the density of tumor vasculature was identified using PECAM-1 staining by
measuring the positive (vascular) and total (tumor) area 6 s.e.m expressed as percentage. n = 8; WT mice injected with LLC1 tumor cells were then
treated with the NOX inhibitor GKT136901 at 40 mg/kg/day by oral administration for 8 days; (c). Graph represents tumor weight in mg 6 s.e.m n=8
per group. (d). Tumor vessel density in tumors from the experiment in (c). Graph shows tumor vascularization expressed in percentage of PECAM-1
positive area 6 s.e.m.; (e). Changes in tumor volume in mm3 after therapeutic treatment starting 8 days post tumor cell injection with GKT136901
(black arrows) or anti-VEGFR2 (DC101) (pointed arrows). Tumor volume is measured using a caliper and the formula V= 4/3p(L/2*l/2*w/2). n = 8; (f).
Blood vessel density in tumors from the experiment in (e). at day 12. Graph shows tumor vascularization expressed in percentage of PECAM-1 positive
area6 s.e.m. WT or PPARa KO mice injected with B16F0 (g) or LLC1 (h) were then treated with the NOX inhibitor GKT136901 at 40 mg/kg/day by oral
administration for 8 days. Graph shows tumor vascularization expressed in percentage of PECAM-1 positive area 6 s.e.m. n = 6. * p,0.05, ** p,0.01
(Student’s t-test).
doi:10.1371/journal.pone.0014665.g006
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ed by NOX-1 deficiency. These differences in gene expression
depended on PPARa transactivation and they explain the reduced
migratory phenotype and tube formation of NOX1 deficient
endothelial cells. PPARa activity, which itself controls PPARa
expression, could be directly regulated by the catalytic activity of
NOX1. Indeed, PPARa activity is regulated by several post-
transcriptional modifications such as phosphorylation or SUMOy-
lation [60,61], which may be ROS sensitive [62]. It has been
previously shown that ROS inactivates phosphatases [63,64] and
activates SUMOylation [62,65]. Thus, upregulation of PPARa
expression and activity in NOX1-deficient cells blocks angiogenic
signaling needed for endothelial cell migration, sprouting and
angiogenesis.
Currently, the anti-VEGF antibody bevacizumab (Avastin), and
several small molecular VEGFR tyrosine kinase inhibitors, are
used as anti-angiogenic drugs to treat patients with advanced
cancers [66,67]. Anti-angiogenic therapy targets non-transformed
endothelial cells and results in the reduced delivery of nutrients
and oxygen to tumor cells. However, concomitant chemotherapy
is needed in order to obtain a survival advantage. Emerging
evidence indicates that tumors treated with anti-angiogenic
therapy elicit compensatory reactions by inducing the production
of alternative angiogenic factors. Thus, the question arises as to
whether anti-NOX therapy could potentially be a therapeutic
approach complementary to anti-VEGF treatment. Indeed,
expression of NOX molecules are induced in vascular endothe-
lium and in tumor cells during the angiogenic switch and
inhibition of NOX1 in both the host and the tumor cells using
the potent NOX1 inhibitor GKT136901, results in reduced tumor
angiogenesis and tumor growth. Moreover NOX1 seems to form a
common angiogenic pathway, at least for signaling induced by
VEGF and FGF. As a result, NOX1 inhibition could bypass the
potential compensatory mechanisms activated by anti-VEGF
therapy.
In conclusion, we have identified NOX1 as a novel mediator of
angiogenesis and as a candidate therapeutic target for anti-
angiogenic therapies in cancer.
Materials and Methods
Mice
NOX1, NOX2, NOX1/2, NOX4 deficient mice were inbred
on the C57BL/6J background for more than 6 generations. The
PPARa null animals were originally described in [68]. All animal
procedures were performed in accordance with the Institutional
Ethical Committee of Animal Care in Geneva and Cantonal
Figure 7. Schematic representation of the role of NOX1 in tumor angiogenesis. (a) Tumor cells and tumor-infiltrating leukocytes during
tumor development produce proangiogenic factors such as VEGF and bFGF. These factors activate the preexisting vessels to form neovessels by
sprouting, migration and proliferation. (b) Endothelial cells receive the angiogenic stimulus by fixation of the angiogenic factor to the surface
receptor. This interaction initiates a signaling cascade, which leads to NOX1 activation through Rac1. NOX1 dependent ROS inhibits the nuclear
hormone receptor PPARa by post-translational modification and transcriptional regulation. This inhibition leads to NF-kB activation and transcription
of angiogenic factors such as MMPs, growth factors or promigratory molecules.
doi:10.1371/journal.pone.0014665.g007
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Veterinary Office. The Institutional Ethical Committee of Animal
Care in Geneva and Cantonal Veterinary Office specifically
approved this study through experimentation IDs: 31.1.1005-
3456-0, 1005-3325-1, 1005-3329-2.
Cells and reagents
Endothelial cell line (thymus derived endothelioma [69]) was
cultured in Dulbecco Modified Eagle medium supplemented with
10% FCS, 100 U/ml Penicillin/Streptomycin, 100 U/ml Gluta-
mine. Primary lung endothelial cells were cultured in DMEM/
HAM F-12 medium supplemented with 20% of FCS, 100 U/ml
Penicillin/Streptomycin, 100 U/ml Glutamine, 100 mg/ml Hep-
arin (Sigma-Aldrich), 10 mg/ml Endothelial cell growth supple-
ment (Upstate). MLEC were used from passage 4 to 6. Human
umbilical vein endothelial cells (HUVEC) were isolated in the
laboratory, cultured in Bullet kit (Lonza) and used from passage 4
to 6. Gelatin, Fibronectin, Fibrinogen, and Aprotinin were
obtained from Sigma Aldrich. Growth factor reduced Matrigel
was from Becton Dickinson. Murine and human bFGF, human
and murine VEGF were from Peprotech. Antibodies against
phospho-p42/44 MAPKinase, total MAPKinase, phosphoThr308
Akt and total Akt were purchased from Cell Signaling Technol-
ogy. Antibody against NF-kB p65 was purchased from SantaCruz
Biotechnology and anti-Actin antibody was kindly provided by Dr
Christine Chaponnier. DC101 hydridoma was purchased from
ATCC (Manassas, VA) and DC101 antibody was expressed and
purified at the protein expression facility at EPFL, Lausanne.
In vivo angiogenesis assay
7 to 10 week old females were injected subcutaneously with
400 ml of growth factor reduced Matrigel supplemented with
500 ng/ml of bFGF. One week later, mice were scanned using
Micro-CT (Skyscan-1076). Mice were scanned before and after
retro-orbital injection of 400 ml iodinated liposomes (BR22,
BracoResearch, Plan-les-Ouates) to visualize the vessel density in
the plug as described previously [70,71].
MLEC isolation
Murine lung endothelial cells were isolated as described
previously [27]. Briefly, whole mouse lungs were digested in
collagenase type I 0.1% (Gibco). Digest lung were plated on
gelatin/collagen/fibronectin-coated flask in DMEM/HAM F-12
medium supplemented with 20% of FCS, 100 U/ml Penicillin/
Streptomycin, 100 U/ml Glutamine, 100 mg/ml Heparin (Sigma-
Aldrich), 10 mg/ml Endothelial cell growth supplement (Upstate).
The following day, macrophages were depleted from the culture
by negative selection using a rat anti-mouse FcgRII/III antibody
coupled to anti-rat coated magnetic beads (Dynal). Cells were then
positively selected twice using the endothelial marker, PECAM-1
(Figure S3).
Quantitative RT-PCR
Total RNA from treated cells was extracted using RNeasy
minikit (Qiagen). Total RNA was reverse-transcribed with the
Superscript III first strand RT-PCR kit (Invitrogen). Quantitative
real-time PCR was performed using SybrGreen master mix
(Applied Biosystems) on Step one plus Real-time PCR machine
(Applied Biosystems). Primer sequences are listed in the Materials
and Methods S1.
Detection of superoxide
Endothelial cells were seeded on glass slides and stained with
dihydroethidium (DHE). Images were captured with an inverted
microscope and analyzed with Metafluor imaging software (MDS
Analytical Technologies). Quantification was performed by
measuring the fluorescence intensity of over minimum 50
endothelial cells per slide.
NOX inhibition in cell free assays and pharmacological
profile of GKT136901
Membranes from NOX2 expressing PMN cells or from cells
overexpressing NOX1 or NOX4 were prepared as previously
described [29]. After resuspension in sonication buffer (11%
sucrose, 120 mM NaCl, 1 mM EGTA in PBS, pH 7.4 for NOX4-
expressing cells) or in relax buffer (10 mM Pipes, 3 mM NaCl,
3.5 mM MgCl2, 0.1 M KCl, pH 7.4), cells were broken by
sonication and centrifuged (200 g, 10 min). The supernatant was
loaded onto a 17/40% (w/v) discontinuous sucrose gradient and
centrifuged (150,000 g for 30 min). Membrane fractions were
collected and stored at 280uC. ROS production measurements of
membranes expressing different NOX subunits was determined as
previously described [30] using the Amplex Red method
(Invitrogen). Membranes prepared from non-transfected cells did
not show NADPH-induced ROS production (data not shown).
Gene silencing
For mouse cells, siRNAs were nucleofected using the Amaxa
technology (Lonza). Gene silencing was assessed 48 hours after
nucleofection by quantitative RT-PCR. For HUVEC, shRNA
vectors (SABiosciences) were nucleofected using Amaxa. Gene
silencing was assessed 48 hours after nucleofection by quantitative
RT-PCR.
Wound healing assay
Wound healing assay was performed as described previously
[72]. Briefly, endothelial cells were plated in Matrigel (Becton
Dickinson) precoated 96 wells plates. One day after plating the cell
monolayer was scratched to make a regular wound. Cells were
allowed to migrate overnight. Migration area was then measured
and calculated using the Metamorph program (MDS Analytical
Technologies).
Endothelial cell sprouting assay
Sprouting assay was performed as described previously [72].
Briefly, endothelial cells were plated in 96 well plates at 8,000 cells
per well in a 3D fibrin gel. Above the gel, 10% FCS containing
DMEM was complemented with 200 KIU/ml of Aprotinin
(Sigma). Length of branches was evaluated using the Metamorph
program. Results are expressed in mm of skeleton length/number
of cells.
Nuclear and cytoplasmic extraction
After stimulation, nuclear and cytoplasmic proteins of endothe-
lial cells were extracted according to Tauzin et al. [73]. Briefly,
cells were incubated in TKM buffer (50 mM Tris-HCl pH 7.4,
25 mM KCl, 5 mM MgCl2 and 1 mM EGTA) containing 1%
Triton and protease inhibitor cocktail CLAP [10 mg/ml chymos-
tatin, leupeptin, antipain and pepstatin A (Sigma) for 30 minutes
on ice, sonicated for 2 minutes and centrifuged at 5000 g for 30
minutes. The pellet and the supernatant were separated and
solubilized in sample buffer.
Western blotting
Cells were stimulated for the indicated time and then lysed in TNT
buffer (50 mM Tris, 150 mM NaCl, 0.5% Triton X-100) comple-
mented with protease inhibitor cocktail CLAP and phosphatase
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inhibitor cocktail [25 mMNaF, 20 mM b-Glycerophosphate, 5 mM
HEPES, 2.5 mM EDTA, 0.5 mM Orthovanadate]. Membranes
were blocked in PBS containing 0.5% BSA and hybridized with
different antibodies. Blots were revealed with peroxidase coupled
secondary reagent (Jackson Immunoresearch) followed by ECL and
quantified by densitometry using Image J software.
Tumor growth assay
5. 105 of LLC1 or B16F0 were injected subcutaneously on the
back of mice. Mice were treated with NOX inhibitor,
GKT136901 or vehicle (Carboxymethyl-cellulose, CMC) at
40 mg/kg everyday per os or i.p with anti-VEGFR2 antibody
(DC101) at 0.8 mg every 2 days. When the control tumor reached
approximately 1 cm in length, mice were sacrificed and the tumor
excised, weighed and frozen. Frozen sections of tumors were
stained with anti-PECAM-1 antibody (rat monoclonal, [74]).
Statistical analysis
All statistical analysis was performed using Anova on multiple
variable analyses and Student’s t-test on paired analyses.
*(p = 0,05), **(p = 0,01), ***(p = 0,001).
Supporting Information
Table S1 Inhibitory effect of the inhibitor GKT 136901 on ROS
producing enzymes, redox-sensitive enzymes and others proteins.
Found at: doi:10.1371/journal.pone.0014665.s001 (0.03 MB
DOC)
Figure S1 MLEC isolation from WT and NOX deficient mice.
a. Flow cytometry analysis of endothelial surface molecules on
isolated MLEC. PECAM-1, VE-Cadherin, ICAM-2 and Meca-32
expression level in MLEC. b. PECAM-1 immunofluorescence
staining of WT, NOX1 KO and NOX4 KO MLEC. Nuclei in
blue (DAPI), and PECAM-1 in purple (Cy5). Images were
acquired with a 40x/1.3 numeric aperture lens and analyzed
using LSM510 Meta microscope (Carl Zeiss).
Found at: doi:10.1371/journal.pone.0014665.s002 (6.76 MB TIF)
Figure S2 Inhibition of NOX-dependent ROS production by
GKT136901 and DPI. a. Concentration-response curves of
GKT136901 on NOX1 (x), NOX2 m), NOX4 (e) and Xanthine
Oxidase (XO) (%). b. Concentration-response curve of DPI on
NOX1 (x), NOX2 (m), NOX4 (e) and Xanthine Oxidase (XO) (%)
Results are from one experiment performed in triplicate, represen-
tative of four performed. Values are presented as means 6 s.e.m.
Found at: doi:10.1371/journal.pone.0014665.s003 (2.02 MB TIF)
Figure S3 NOXdependant ROS blocking agents efficiently block
endothelial cell migration and branching capacities. a. Migration of
endothelial cells was analyzed by a wound-healing assay in presence
of different inhibitors that block NADPH dependant ROS
production. b. Tubular structure formation was measured by 3D
culture using the mouse endothelial cell line in presence of different
inhibitors that block NADPH dependant ROS production. Results
are expressed in % of control 6 s.e.m, n= 3.
Found at: doi:10.1371/journal.pone.0014665.s004 (5.89 MB TIF)
Figure S4 NOX1 over-expression enhances endothelial cell
migration and tube-like structure formation. a. In vitro migration
was analyzed by wound-healing assay using endothelioma cell
lines transfected with NOX1 expressing vector. b. Tubular
structure formation was measured by 3D culture of endothelioma
cell lines transfected with NOX1 expressing vector. Results are
expressed in % of control 6 s.e.m. *p, 0.05 using Student’s t-test.
Found at: doi:10.1371/journal.pone.0014665.s005 (5.88 MB TIF)
Figure S5 AKT but ERK 1/2 activation is affected by NOX1
deficiency. NOX1-deficient MLEC does not activate Akt after
bFGF stimulation but present no difference in ERK1/2 activation.
a. Western blot analysis of Akt phosphorylation in WT and NOX1-
deficient MLEC after 10 min stimulation with 20 ng/ml of bFGF.
The graph shows the abundance of phosphorylated Akt relative to
total Akt6 s.e.m as determined by densitometry. n= 3. b. Western
blot analysis of ERK1/2 phosphorylation in WT and NOX1-
deficient MLEC stimulated for 10 min with 20 ng/ml of bFGF. The
graph shows the abundance of phosphorylated ERK1/2 relative to
total ERK1/2 6 s.e.m as determined by densitometry. n= 3.
Found at: doi:10.1371/journal.pone.0014665.s006 (6.13 MB TIF)
Figure S6 NF-kB nuclear translocation is inhibited in the
absence of NOX1 and dependent on PPARa activation. VEGF or
b-FGF stimulation of endothelial cells induced p65 NF-kB
translocation into the nucleus. This nuclear translocation is not
observed in NOX1-deficient cells but restored by PPARa
antagonist treatment (GW6471). Immunofluorescence, anti-p65
NF-kB of MLEC (a) and endothelioma cell lines (b) stimulated
with VEGF or bFGF in presence or absence of GW6471 (10mM).
NF-kB in green (Alexa 488), nuclei in blue (DAPI). Scale bar
represent 20 mm. Images were acquired with a 40x/1.3 numeric
aperture and analyzed using LSM510 confocal microscope (Carl
Zeiss).
Found at: doi:10.1371/journal.pone.0014665.s007 (7.09 MB TIF)
Figure S7 Effect of GKT 136901 on tumor cells. a. LLC1 and
B16F0 cell proliferation was measured by EdU incorporation and
propidium iodide staining of DNA content, 24h after incubation
with 10 mM of GKT136901. b. LLC1 apoptosis was measured by
AnnexinV/PI staining after 24h of incubation with 10 mM of
GKT136901. c. ROS levels produced by LLC1 are inhibited by
GKT136901. ROS production was quantified by DHE substrate
1h after incubation with 10 mM of the inhibitor. *** p,0.001
(student t-test).
Found at: doi:10.1371/journal.pone.0014665.s008 (6.11 MB TIF)
Figure S8 Non toxic effect GKT 136901 on mice organs. Heart
(a), Kidney (b), Liver (c) and Lung (d) of mice treated orally with
vehicle or with vehicle plus GKT136901 inhibitor at 40 mg/kg per
day during 8 days, stained by Hematoxilin/Eosin. Scale bars
represent 100 mm on the full picture and 20 mm on the zoom.
Images were acquired with a 20x/0.8 numeric aperture and
analyzed using Mirax (Carl Zeiss).
Found at: doi:10.1371/journal.pone.0014665.s009 (8.38 MB TIF)
Materials and Methods S1 Real-time PCR primer sequence
list.
Found at: doi:10.1371/journal.pone.0014665.s010 (0.05 MB
DOC)
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